Application of PD-1 inhibitor Camrelizumab in advanced malignancies
10.11855/j.issn.0577-7402.2020.06.16
- VernacularTitle: PD -1抑制剂卡瑞利珠单抗在晚期恶性肿瘤中的应用进展
- Author:
Xiang-Chong LUO
1
Author Information
1. Department of Cardiothoracic Surgery, Qujing Second People's Hospital
- Publication Type:Journal Article
- Keywords:
Camrelizumab;
Immunotherapy;
Neoplasms;
Programmed cell death 1 receptor;
Programmed death 1 inhibitor;
Therapeutic target
- From:
Medical Journal of Chinese People's Liberation Army
2020;45(6):672-679
- CountryChina
- Language:Chinese
-
Abstract:
With the remarkable achievements made in the treatment targeted at tumor immune checkpoints, more and more new immunotherapy drugs have been applied to the malignancies treatment. Camrelizumab (AiRuiKa) is a novel human immunoglobulin G4 (IgG4) monoclonal antibody (mAb), which can target the programmed death 1 (PD-1) and block its binding to the programmed death ligand 1 (PD-L1), so as to restore the body's immune function and achieve anti-tumor effect. The drug was officially approved by National Medical Products Administration (NMPA) on May 29, 2019 for use in patients with recurrent or refractory classical Hodgkin's lymphoma (cHL) who are treated with at least second-line systemic therapy. In addition, the drug showed good anti-tumor activity in esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer (NSCLC), and gastric cancer (GC) and gastroesophageal junction cancer (EGJC). The research progress of camrelizumab on mechanism of action, pharmacodynamics and pharmacokinetics, clinical studies, adverse reactions etc. were reviewed in present paper.
